A promising clinical trial shows that a combination of paxalisib, pembrolizumab, and chemotherapy significantly reduces circulating tumor cells in metastatic triple-negative breast cancer.

USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 10, 2025 /PRNewswire/ -- USA News Group News Commentary - Cancer rates are rising everywhere ...

The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads ...